Selinexor: Targeting a novel pathway in multiple myeloma
eJHaem, 2023 Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo +9 more
doaj +1 more source
A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease: Modelling Therapies for Multiple Myeloma Induced Bone Disease [PDF]
, 2015 Multiple myeloma bone disease is devastating for patients and a major cause of morbidity. The disease leads to bone destruction by inhibiting osteoblast activity while stimulating osteoclast activity.
Fagan, Michael J. +2 more
core +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2023 Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD +9 more
doaj +1 more source
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Cells, 2022 Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein +2 more
doaj +1 more source
Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]
, 2012 Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
A Barbarulo +63 more
core +2 more sources
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Antibodies, 2017 2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho +6 more
doaj +1 more source
Living with multiple myeloma: A focus group study of unmet needs and preferences for survivorship care [PDF]
, 2017 Purpose: To describe the unmet informational, psychological, emotional, social, practical, and physical needs and preferences for posttreatment survivorship care of individuals living with multiple myeloma to inform the development of relevant ...
Bulsara, C +8 more
core +3 more sources
Haematologica, 2018 Allogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe.
Jennifer Mosebach +8 more
doaj +1 more source
Myeloma multiplex with pulmonary dissemination [PDF]
, 2014 Introduction. Multiple myeloma is a hemathological malignancy characterized by the clonal proliferation of plasma cells in the bone the marrow. Extramedullary dissemination of multiple myeloma is uncommon.
Maksić Đoko +9 more
core +1 more source
Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools
Diagnostics, 2020 Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife +2 more
doaj +1 more source